KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Receivables (2016)

Historic Change in Receivables for Novavax (NVAX) over the last 7 years, with Q4 2016 value amounting to -$356000.0.

  • Novavax's Change in Receivables rose 8231.5% to -$356000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was -$2.1 million, marking a year-over-year increase of 7556.32%. This contributed to the annual value of -$144.4 million for FY2021, which is 4125.42% up from last year.
  • Novavax's Change in Receivables amounted to -$356000.0 in Q4 2016, which was up 8231.5% from $236000.0 recorded in Q3 2016.
  • In the past 5 years, Novavax's Change in Receivables registered a high of $2.8 million during Q4 2014, and its lowest value of -$6.0 million during Q2 2015.
  • Its 5-year average for Change in Receivables is -$361850.0, with a median of -$233500.0 in 2012.
  • In the last 5 years, Novavax's Change in Receivables surged by 166125.0% in 2014 and then tumbled by 256923.08% in 2016.
  • Novavax's Change in Receivables (Quarter) stood at -$1.5 million in 2012, then soared by 110.97% to $160000.0 in 2013, then soared by 1661.25% to $2.8 million in 2014, then crashed by 171.43% to -$2.0 million in 2015, then surged by 82.31% to -$356000.0 in 2016.
  • Its Change in Receivables was -$356000.0 in Q4 2016, compared to $236000.0 in Q3 2016 and -$26000.0 in Q2 2016.